Skip to main content

Advertisement

SpringerLink
Log in

Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Cerebrotendinous xanthomatosis (CTX) is a rare neurometabolic disease due to defective activity of sterol 27-hydroxylase, with plasma and tissue cholestanol storage. Clinical phenotype is characterized by both systemic manifestations and neurological signs. Therapy with chenodeoxycholic acid (CDCA) suppresses abnormal bile acid synthesis. The purpose of the study was to assess the frequency and clinical relevance of spasticity in the CTX phenotype and to study the usefulness of transcranial magnetic stimulation (TMS) in detecting corticospinal tract damage and monitoring the effects of replacement therapy. Twenty-four CTX patients underwent clinical evaluation including general disability scores, pyramidal and cerebellar function scales, assessment of serum cholestanol and TMS. Nine patients who started CDCA therapy at baseline received clinical and neurophysiological follow up. All patients showed signs of pyramidal damage which were relevant for clinical disability in 18 out of 24 cases (75%), resulting in spastic paraparesis. TMS revealed corticospinal alterations even in subjects with mild clinical signs of corticospinal tract involvement. After CDCA treatment, serum cholestanol decreased to normal concentrations in all patients. Clinical picture was unchanged in seven out of nine cases; in two others pyramidal signs disappeared. A reduction in abnormal neurophysiological parameters was found. Spastic paraparesis is the most frequent and relevant neurological feature in CTX patients. Replacement treatment with CDCA can prevent the progression of pyramidal damage, especially if started early in the course of the disease. TMS represents a sensitive indicator of corticospinal tract dysfunction and subclinical improvements in pyramidal function after CDCA therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Björkhem I, Boberg KM, Leitersdorf E (2001) Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, 8th edn. McGraw-Hill, New York, pp 2961–2988

    Google Scholar 

  2. Lee MH, Hazard S, Carpten JD et al (2001) Fine-mapping, mutation analysis, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res 42:159–169

    PubMed  CAS  Google Scholar 

  3. Cali JJ, Russell DW (1991) Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 266:7774–7778

    PubMed  CAS  Google Scholar 

  4. Salen G, Shefer S, Tint GS et al (1985) Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26. J Clin Invest 76:744–751

    Article  PubMed  CAS  Google Scholar 

  5. Federico A, Dotti MT (2003) Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 18:633–638

    Article  PubMed  Google Scholar 

  6. Cruysberg JR (2002) Cerebrotendinous xanthomatosis: juvenile cataract and chronic diarrhea before the onset of neurologic disease. Arch Neurol 59:1975

    Article  PubMed  Google Scholar 

  7. Federico A, Dotti MT, Loré F, Nuti R (1993) Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. J Neurol Sci 115:67–70

    Article  PubMed  CAS  Google Scholar 

  8. Arlazoroff A, Roitberg B, Werber E et al (1991) Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. Epilepsia 32:657–661

    Article  PubMed  CAS  Google Scholar 

  9. Dotti MT, Federico A, Garuti R, Calandra S (2000) Cerebrotendinous xanthomatosis with predominant parkinsonian syndrome: further confirmation of the clinical heterogeneity. Mov Disord 15:1017–1019

    Article  PubMed  CAS  Google Scholar 

  10. Alcalay R, Wu S, Patel S, Frucht S (2009) Oromandibular dystonia as a complication of cerebrotendinous xanthomatosis. Mov Disord 24(9):1397–1399

    Article  PubMed  Google Scholar 

  11. Siebner HR, Berndt S, Conrad B (1996) Cerebrotendinous xanthomatosis without tendon xanthomas mimicking Marinesco–Sjoegren syndrome: a case report. J Neurol Neurosurg Psychiatry 60(5):582–585

    Article  PubMed  CAS  Google Scholar 

  12. Gilad R, Lampl Y, Lev D, Sadeh M (1999) Cerebrotendinous xanthomatosis without xanthomas. Clin Genet 56:405–406

    Article  PubMed  CAS  Google Scholar 

  13. Verrips A, van Engelen BG, Wevers RA et al (2000) Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. Arch Neurol 57:520–524

    Article  PubMed  CAS  Google Scholar 

  14. Campdelacreu J, Munoz E, Cervera A et al (2002) Cerebrotendinous xanthomatosis without tendinous xanthomas: presentation of two cases. Neurologia 17:647–650

    PubMed  CAS  Google Scholar 

  15. Okuma H, Kitagawa Y, Tokuoka K, Takagi S (2007) Cerebrotendinous xanthomatosis with cerebellar ataxia as the chief symptom. Intern Med 46:1259–1261

    Article  PubMed  Google Scholar 

  16. Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876

    PubMed  CAS  Google Scholar 

  17. De Stefano N, Dotti MT, Mortilla M, Federico A (2001) Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 124:121–131

    Article  PubMed  Google Scholar 

  18. Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311:1649–1652

    Article  PubMed  CAS  Google Scholar 

  19. Berginer VM, Gross B, Morad K et al (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123(1):143–147

    Article  PubMed  Google Scholar 

  20. van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607

    PubMed  Google Scholar 

  21. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    PubMed  CAS  Google Scholar 

  22. Koopman BJ, van der Molen JC, Wolthers BG et al (1984) Capillary gas chromatographic determination of cholestanol/cholesterol ratio in biological fluids. Its potential usefulness for the follow-up of some liver diseases and its lack of specificity in diagnosing CTX (cerebrotendinous xanthomatosis). Clin Chim Acta 137(3):305–315

    Article  PubMed  CAS  Google Scholar 

  23. Federico A, Dotti MT (1996) Cerebrotendinous xanthomatosis. In: Moser HW (ed) Handbook of Clinical Neurology 22(66):599–613

  24. Rossini PM, Rossi S (1998) Clinical applications of motor evoked potentials. Electroencephalogr Clin Neurophysiol 106:180–194

    Article  PubMed  CAS  Google Scholar 

  25. Kobayashi M, Pascual-Leone A (2003) Transcranial magnetic stimulation in neurology. Lancet Neurol 2:145–156

    Article  PubMed  Google Scholar 

  26. Hallett M (2007) Transcranial magnetic stimulation: a primer. Neuron 55:187–199

    Article  PubMed  CAS  Google Scholar 

  27. Rossini PM, Barker AT, Berardelli A et al (1994) Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 91(2):79–92

    Article  PubMed  CAS  Google Scholar 

  28. Passero S, Rossi S, Giannini F, Nuti D (2001) Brain-stem compression in vertebrobasilar dolichoectasia. A multimodal electrophysiological study. Clin Neurophysiol 112:1531–1539

    Article  PubMed  CAS  Google Scholar 

  29. Centonze D, Koch G, Versace V et al (2007) Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology 68(13):1045–1050

    Article  PubMed  CAS  Google Scholar 

  30. Knikou M (2008) The H-reflex as a probe: pathways and pitfalls. J Neurosci Methods 171(1):1–12

    Article  PubMed  Google Scholar 

  31. Verrips A, Hoefsloot LH, Steenbergen GC et al (2000) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123(Pt 5):908–919

    Article  PubMed  Google Scholar 

  32. Verrips A, Nijeholt GJ, Barkhof F et al (1999) Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain 122(Pt 8):1589–1595

    Article  PubMed  Google Scholar 

  33. Clemen CS, Spottke EA, Lütjohann D et al (2005) Cerebrotendinous xanthomatosis: a treatable ataxia. Neurology 64:1476

    PubMed  CAS  Google Scholar 

  34. Mukherjee AA, Chawla BP, Rathi SS, Puthran RS (2007) Cerebrotendinous xanthomatosis: a treatable cause of metabolic ataxia. J Assoc Physicians India 55:655–657

    PubMed  CAS  Google Scholar 

  35. Guerrera S, Stromillo ML, Mignarri A et al (2010) Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry 81(11):1189–1193

    Article  PubMed  CAS  Google Scholar 

  36. Rossini PM, Rossi S (2007) Transcranial magnetic stimulation. Diagnostic, therapeutic and research potential. Neurology 68:484–488

    Article  PubMed  Google Scholar 

  37. Ugawa Y, Kohara N, Shimpo T, Mannen T (1988) Central motor and sensory conduction in adrenoleukomyeloneuropathy, cerebrotendinous xanthomatosis, HTLV-1-associated myelopathy and tabes dorsalis. J Neurol Neurosurg Psychiatry 51:1069–1074

    Article  PubMed  CAS  Google Scholar 

  38. Mondelli M, Rossi A, Scarpini C et al (1992) Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid. Arch Neurol 49:469–475

    PubMed  CAS  Google Scholar 

  39. Restuccia D, Di Lazzaro V, Servidei S et al (1992) Somatosensory and motor evoked potentials in the assessment of cerebrotendinous xanthomatosis before and after treatment with chenodeoxycholic acid: a preliminary study. J Neurol Sci 112:139–146

    Article  PubMed  CAS  Google Scholar 

  40. Mondelli M, Sicurelli F, Scarpini C et al (2001) Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study. J Neurol Sci 190:29–33

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Authors thank Benito Vecchiarelli for his excellent technical assistance during some of the neurophysiological recordings.

Author information

Authors and Affiliations

  1. Neurometabolic Unit, Department of Neurological, Neurosurgical and Behavioural Sciences, University of Siena, Viale Bracci 2, 53100, Siena, Italy

    A. Mignarri, G. N. Gallus, A. Federico & M. T. Dotti

  2. Section of Neurology and Clinical Neurophysiology, Department of Neuroscience, University of Siena, Siena, Italy

    S. Rossi & M. Ballerini

  3. Department of Experimental Medicine, Medical School, University of Milano-Bicocca, Monza, Italy

    M. Del Puppo

  4. Unit of Diagnostic and Therapeutic Neuroradiology, Azienda Ospedaliera Senese, Policlinico Le Scotte, Siena, Italy

    P. Galluzzi

Authors
  1. A. Mignarri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Ballerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. N. Gallus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Del Puppo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Galluzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Federico
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. T. Dotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. T. Dotti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mignarri, A., Rossi, S., Ballerini, M. et al. Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol 258, 783–790 (2011). https://doi.org/10.1007/s00415-010-5829-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-010-5829-4

Keywords

Search

Navigation